DRIVERS OF TREATMENT PREFERENCES IN HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (HR-NMIBC) PATIENTS: QUALITATIVE INTERVIEWS TO INFORM A PATIENT-PREFERENCE STUDY

被引：0
|
作者：
Mason, B. [1 ]
Eccleston, A. [2 ]
Gater, A. [1 ]
Hauber, B. [3 ]
Thompson, A. [3 ]
Coulter, J. [4 ]
Guy, M. [1 ]
Nunes, Ayala L. [1 ]
Brinkmann, J. [5 ]
Hallworth, P. [6 ]
Cappelleri, J. [7 ]
Bell, B. [6 ]
Chang, J. [3 ]
Satkunasivam, R. [8 ]
机构：
[1] Adelphi Values Ltd, Bollington, Cheshire, England
[2] Pfizer, Tadworth, England
[3] Pfizer, New York, NY USA
[4] Pfizer Inc, Grand Rapids, MI USA
[5] Pfizer Pharma GmbH, Berlin, Germany
[6] Adelphi Res, Bollington, Cheshire, England
[7] Pfizer Inc, New York, NY USA
[8] Houston Methodist Hosp, Houston, TX USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCR235
引用
收藏
页码：S494 / S495
页数：2
相关论文
共 50 条
  • [21] T1G3 HIGH-RISK NMIBC (NON-MUSCLE INVASIVE BLADDER CANCER): CONSERVATIVE TREATMENT VERSUS IMMEDIATE CYSTECTOMY
    Busetto, Gian Maria
    Giovannone, Riccardo
    Antonini, Gabriele
    Gentile, Vincenzo
    De Berardinis, Ettore
    ANTICANCER RESEARCH, 2012, 32 (05) : 1868 - 1868
  • [22] Combination Therapy for Patients with High-risk non-muscle invasive Bladder Cancer (HR-NMIBC) A randomized, open-label, multi-center, world-wide, Phase III Study of Durvalumab and Bacillus Calmette-Guerin (BCG) administered as a Combination Therapy compared to BCG alone in Patients with High-risk non-muscle invasive Bladder Cancer (POTOMAC) - AB 69/18 of the AUO
    Rexer, H.
    Merseburger, A.
    Boegemann, M.
    AKTUELLE UROLOGIE, 2019, 50 (04) : 345 - 346
  • [23] T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy
    E. De Berardinis
    G. M. Busetto
    G. Antonini
    R. Giovannone
    V. Gentile
    International Urology and Nephrology, 2011, 43 : 1047 - 1057
  • [24] Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer
    Zieger, Karsten
    Wiuf, Carsten
    Jensen, Klaus Moller-Ernst
    Orntoft, Torben Falck
    Dyrskjot, Lars
    BMC CANCER, 2009, 9
  • [25] Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer
    Karsten Zieger
    Carsten Wiuf
    Klaus Møller-Ernst Jensen
    Torben Falck Ørntoft
    Lars Dyrskjøt
    BMC Cancer, 9 (1)
  • [26] Current approaches for identifying high-risk non-muscle invasive bladder cancer
    Sanli, Oner
    Lotan, Yair
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (03) : 223 - 235
  • [27] Disparities in the prevalence and management of high-risk non-muscle invasive bladder cancer
    Estevez, Angela
    Kaul, Sumedh
    Fleishman, Aaron
    Korets, Ruslan
    Chang, Peter
    Wagner, Andrew
    Bellmunt, Joaquim
    Olumi, Aria F.
    Rayala, Heidi
    Gershman, Boris
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (05) : 255e15 - 255e21
  • [28] DISPARITIES IN THE PREVALENCE AND MANAGEMENT OF HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
    Estevez, Angela
    Kaul, Sumedh
    Fleishman, Aaron
    Korets, Ruslan
    Chang, Peter
    Wagner, Andrew
    Bellmunt, Joaquim
    Olumi, Aria
    Rayala, Heidi
    Gershman, Boris
    JOURNAL OF UROLOGY, 2022, 207 (05): : E1004 - E1004
  • [29] Neoadjuvant Chemohyperthermia (CHT) for the Treatment of High-Risk Non-Muscle Invasive Bladder Cancer: A Phase I Study
    Sousa, A.
    UROLOGY, 2012, 80 (03) : S65 - S65
  • [30] A phase 1/2 study of detalimogene voraplasmid (EG-70) intravesical monotherapy for patients with high-risk non-muscle invasive bladder cancer (NMIBC).
    Chang, Sam S.
    Dickstein, Rian J.
    Jayram, Gautam
    Shore, Neal D.
    Liu, Jen-Jane
    Lotan, Yair
    Satkunasivam, Raj
    Schuckman, Anne K.
    Steinberg, Gary D.
    Taylor, John R.
    Linback, Tammy
    Pruthi, Raj
    Sullivan, James C.
    Tosone, Christine
    Kamat, Ashish M.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : TPS886 - TPS886
12345